219 documents

Read All
23:20 , Apr 26, 2019 |  BC Extra  |  Company News

Express Scripts excludes Lilly's low cost insulin generic from preferred formulary

Express Scripts Holding Co. (NASDAQ:ESRX) excluded from its 2019 preferred formulary Eli Lilly's newly launched generic insulin product, reinforcing the idea that PBMs want bigger rebates, not cheaper drugs. PBMs and insurance companies typically require...
Read More
23:56 , Mar 26, 2019 |  BC Extra  |  Company News

Louisiana picks Gilead's generics unit for HCV subscription model

Louisiana has chosen to partner with Gilead's generics subsidiary to access a generic version of HCV drug Epclusa sofosbuvir/velpatasvir through a subscription-based model. The state's Department of Health and Department of Corrections said the deal...
Read More
00:22 , Mar 5, 2019 |  BC Extra  |  Company News

Lilly offers cheaper insulin, pressuring competitors

Lilly will offer a new, lower cost insulin that is substitutable for Humalog at pharmacies. While at least one patient group says it's not enough, the move puts pressure on the pharma’s competitors. Months of...
Read More
18:54 , Feb 22, 2019 |  BC Week In Review  |  Company News

Subscription payment model for HCV drugs will reduce costs in Australia

Australia's "subscription" model for HCV drugs is more cost effective than standard payment models, according to a paper published Feb. 14 in the New England Journal of Medicine . In 2015, Australia negotiated a five-year...
Read More
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
Read More
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
Read More
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
Read More
18:38 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

China approves Descovy, Harvoni, Hemlibra

China's National Medical Products Administration (NMPA) has issued new approvals for three drugs marketed in the U.S. and EU: Descovy emtricitabine/tenofovir alafenamide and Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), and Hemlibra emicizumab-kxwh from Roche...
Read More
20:34 , Dec 4, 2018 |  BC Extra  |  Company News

China approves Descovy, Harvoni, Hemlibra

China's National Medical Products Administration (NMPA) has issued new approvals for three drugs marketed in the U.S. and EU: Descovy emtricitabine/tenofovir alafenamide and Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), and Hemlibra emicizumab-kxwh from Roche...
Read More
00:25 , Nov 14, 2018 |  BC Extra  |  Politics & Policy

Epclusa, Harvoni first alternatives on Express Scripts' new formulary

Express Scripts Holding Co. (NASDAQ:ESRX) introduced a new formulary Tuesday to help lower out-of-pocket costs and reduce dependence on rebated brand products by including authorized alternative medicines with lower list prices. HCV drugs Epclusa sofosbuvir/velpatasvir...
Read More